Literature DB >> 28324149

[Outpatient care and disease burden of rheumatoid arthritis : Results of a linkage of claims data and a survey of insured persons].

K Albrecht1, A Luque Ramos2, J Callhoff3, F Hoffmann2, K Minden3,4, A Zink3,4.   

Abstract

BACKGROUND: Healthcare of patients with rheumatoid arthritis (RA) in Germany has mainly been evaluated in the past in RA cohorts from specialized arthritis centers. This study investigated rheumatological care on a population basis, using claims data from a nationwide statutory health insurance fund (BARMER GEK) in combination with patient-reported outcomes from a questionnaire survey of insured persons with RA.
METHODS: Data from insurants aged 18-79 years with M05 (seropositive RA) or M06 (other RA, ICD-10) diagnoses were analyzed concerning diagnostics, medication and prescribing physician. A 31-item questionnaire covering patient reported diagnosis, healthcare utilization and burden of illness was sent to a stratified random sample of 6193 insured persons. Data from the respondents regarding rheumatological care and disease status were evaluated.
RESULTS: In 2013 and 2014, a total of 96,921 adults with M05 or M06 diagnosis were insured. The questionnaire was answered by 51% of the sample and of these 81% confirmed the RA diagnosis. RA had been diagnosed by a rheumatologist in 59% of the cases, 70% reported moderate to severe pain and 46% had functional disability. Between at least 40% (claims data) and up to 68% (respondents) were in specialized rheumatological care. Treatment with disease-modifying antirheumatic drugs (DMARDs) was 61% (claims data) and 63% (respondents) in persons in rheumatological care but only 18% outside rheumatological care.
CONCLUSION: The results indicate that specialized rheumatological care is required to provide adequate treatment for patients with RA in Germany. Patients with higher age and patients with M06 diagnosis had less drug prescriptions and were less frequently treated by rheumatologists.

Entities:  

Keywords:  Diagnostics; Disease burden; Drug treatment; Health care; Rheumatoid arthritis

Mesh:

Substances:

Year:  2018        PMID: 28324149     DOI: 10.1007/s00393-017-0294-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  9 in total

1.  [Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA].

Authors:  K Albrecht; J Callhoff; E Edelmann; G Schett; M Schneider; A Zink
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

2. 

Authors:  S Hense; A Luque Ramos; J Callhoff; K Albrecht; A Zink; F Hoffmann
Journal:  Z Rheumatol       Date:  2016-09-07       Impact factor: 1.372

3.  [Therapy of rheumatoid arthritis with methotrexate. Claims data analysis of treatment patterns].

Authors:  J Zeidler; H Zeidler; J-M Graf von der Schulenburg
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

4.  [Healthcare research in rheumatology. Current state].

Authors:  A Zink
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

5.  Advance and unmet need of health care for patients with rheumatoid arthritis in the German population--results from the German Rheumatoid Arthritis Population Survey (GRAPS).

Authors:  Gisela Westhoff; Matthias Schneider; Heiner Raspe; Henning Zeidler; Claus Runge; Timm Volmer; Angela Zink
Journal:  Rheumatology (Oxford)       Date:  2009-03-25       Impact factor: 7.580

6.  [Medical treatment of rheumatoid arthritis in 2014 : Current data from the German Collaborative Arthritis Centers].

Authors:  K Albrecht; D Huscher; T Eidner; S Kleinert; S Späthling-Mestekemper; S Bischoff; A Zink
Journal:  Z Rheumatol       Date:  2017-02       Impact factor: 1.372

7.  [The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision].

Authors:  D Pattloch; A Richter; B Manger; R Dockhorn; L Meier; H-P Tony; A Zink; A Strangfeld
Journal:  Z Rheumatol       Date:  2017-04       Impact factor: 1.372

Review 8.  Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods.

Authors:  Gundula Krack; Henning Zeidler; Jan Zeidler
Journal:  Drugs Real World Outcomes       Date:  2016-09

9.  Frequency and trends of disease-modifying antirheumatic drug (DMARD) use in Germany.

Authors:  Alexander M Fassmer; Edeltraut Garbe; Niklas Schmedt
Journal:  Pharmacol Res Perspect       Date:  2016-09-27
  9 in total
  12 in total

1.  [Health care and disease burden in persons with axial spondyloarthritis in Germany].

Authors:  H Haibel; I Redeker; A Zink; J Callhoff; U Marschall; F Hoffmann; J Sieper; D Poddubnyy
Journal:  Z Rheumatol       Date:  2019-11       Impact factor: 1.372

Review 2.  [Long-term trends in rheumatology care : Achievements and deficits in 25 years of the German national rheumatology database].

Authors:  K Albrecht; J Callhoff; A Zink
Journal:  Z Rheumatol       Date:  2019-10       Impact factor: 1.372

3.  Rheumatologic care of nursing home residents with rheumatoid arthritis: a comparison of the year before and after nursing home admission.

Authors:  Andres Luque Ramos; Katinka Albrecht; Angela Zink; Falk Hoffmann
Journal:  Rheumatol Int       Date:  2017-08-18       Impact factor: 2.631

4.  [Cost of illness in axial spondylarthritis for patients with and without tumor necrosis factor inhibitor treatment: results of a routine data analysis].

Authors:  I Redeker; J Callhoff; F Hoffmann; J Saam; H Haibel; J Sieper; A Zink; D Poddubnyy
Journal:  Z Rheumatol       Date:  2020-02       Impact factor: 1.372

5.  [Prevalence, comorbidity and interdisciplinary treatment of rheumatoid arthritis - Insurance data on outpatient and inpatient care in Baden-Württemberg].

Authors:  A Strahl; O Schneider; J Frankenhauser-Mannuß; S Knapstein; C Hermann; B Lembeck; H-M Lorenz; W Rüther; J Flechtenmacher
Journal:  Z Rheumatol       Date:  2018-03       Impact factor: 1.372

Review 6.  [Reality of care for musculoskeletal diseases at the population level : Results of the PROCLAIR collaborative project. German version].

Authors:  J Callhoff; K Albrecht; F Hoffmann; D Poddubnyy; K-P Günther; A Zink
Journal:  Z Rheumatol       Date:  2019-10       Impact factor: 1.372

7.  Persistence and treatment-free interval in patients being prescribed biological drugs in rheumatology practices in Germany.

Authors:  Karel Kostev; Louis Jacob
Journal:  Eur J Clin Pharmacol       Date:  2019-01-21       Impact factor: 2.953

8.  [Prescription of analgesics in patients with rheumatic diseases in Germany : A claims data analysis. German version].

Authors:  K Albrecht; U Marschall; J Callhoff
Journal:  Z Rheumatol       Date:  2021-02-26       Impact factor: 1.372

9.  Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.

Authors:  Annika Steffen; Jakob Holstiege; Kerstin Klimke; Manas K Akmatov; Jörg Bätzing
Journal:  Rheumatol Int       Date:  2018-10-10       Impact factor: 2.631

10.  Prescription of analgesics in patients with rheumatic diseases in Germany : A claims data analysis.

Authors:  K Albrecht; U Marschall; J Callhoff
Journal:  Z Rheumatol       Date:  2021-04-07       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.